. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: JACC Heart Fail. 2015 Sep;3(9):715–723. doi: 10.1016/j.jchf.2015.03.015

Table 1.

Cyclic GMP Pharmacokinetics.

	PcGMP Cmax (pmol/ml)	PcGMP Tmax (min)	PcGMP AUClast (pmol*min/ml)	PcGMP T1/2 (min)	UcGMPV Cmax (pmol/ml)	UcGMPV Tmax (min)	UcGMPV AUClast (pmol*min/ml)	UcGMPV T1/2 (min)
ANP	57.7 ± 11.6	6.0 ± 0.6	1205.6 ± 176.9	13.3 ± 1.8	5255.4 ± 816.7	14.0 ± 2.4	191179.3 ± 38770.7	25.9 ± 3.6
BNP	108.3 ± 14.2^*	9.0 ± 1.8	3498.6 ± 488.1^*	17.7 ± 1.6	10415.2 ± 1190.6^*	18.0 ± 3.7	498780.3 ± 51977.7^*	23.6 ± 2.2
ProANP	51.5 ± 4.7^†	7.6 ± 0.7	2720.0 ± 342.9^*	*40.3 ± 6.7^^†**	5984.9 ± 417.9^†	20.0 ± 3.2	383668.1 ± 28010.2^*	*44.8 ± 3.2^^†**

PcGMP, plasma cGMP levels; UcGMPV, urinary cGMP excretion; Cmax, maximum concentration; Tmax, time to maximum concentration; AUClast, area under the concentration-time curve from time 0 to the last measurable concentration (Tlast=180 min); and T1/2, half-life.

p<0.05 vs ANP

^†

p<0.05 vs BNP.